Report cover image

Global FGF-2 Inhibitors Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 207 Pages
SKU # APRC20361611

Description

Summary

According to APO Research, The global FGF-2 Inhibitors market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for FGF-2 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for FGF-2 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for FGF-2 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for FGF-2 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of FGF-2 Inhibitors include Advenchen Laboratories, ArQule, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International and Eddingpharm, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for FGF-2 Inhibitors, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of FGF-2 Inhibitors, also provides the revenue of main regions and countries. Of the upcoming market potential for FGF-2 Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the FGF-2 Inhibitors revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global FGF-2 Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for FGF-2 Inhibitors revenue, projected growth trends, production technology, application and end-user industry.

FGF-2 Inhibitors Segment by Company

Advenchen Laboratories
ArQule
AVEO Pharmaceuticals
Batu Biologics
Boehringer Ingelheim
Bristol-Myers Squibb Company
Celon Pharma
Debiopharm International
Eddingpharm
Eli Lilly and Company
Hutchison MediPharma
Principia Biopharma
Santa Cruz Biotechnology
Vichem Chemie Research
AstraZeneca
Amgen
Novartis
Eisai
FGF-2 Inhibitors Segment by Type

EDP-317
Debio-1347
CPL-043
BAY-1163877
AZD-4547
ASP-5878
Others
FGF-2 Inhibitors Segment by Application

Clinic
Hospital
Others
FGF-2 Inhibitors Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FGF-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of FGF-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FGF-2 Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of FGF-2 Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of FGF-2 Inhibitors company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, FGF-2 Inhibitors revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

207 Pages
1 Market Overview
1.1 Product Definition
1.2 FGF-2 Inhibitors Market by Type
1.2.1 Global FGF-2 Inhibitors Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 EDP-317
1.2.3 Debio-1347
1.2.4 CPL-043
1.2.5 BAY-1163877
1.2.6 AZD-4547
1.2.7 ASP-5878
1.2.8 Others
1.3 FGF-2 Inhibitors Market by Application
1.3.1 Global FGF-2 Inhibitors Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 FGF-2 Inhibitors Market Dynamics
2.1 FGF-2 Inhibitors Industry Trends
2.2 FGF-2 Inhibitors Industry Drivers
2.3 FGF-2 Inhibitors Industry Opportunities and Challenges
2.4 FGF-2 Inhibitors Industry Restraints
3 Global Growth Perspective
3.1 Global FGF-2 Inhibitors Market Perspective (2020-2031)
3.2 Global FGF-2 Inhibitors Growth Trends by Region
3.2.1 Global FGF-2 Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global FGF-2 Inhibitors Market Size by Region (2020-2025)
3.2.3 Global FGF-2 Inhibitors Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global FGF-2 Inhibitors Revenue by Players
4.1.1 Global FGF-2 Inhibitors Revenue by Players (2020-2025)
4.1.2 Global FGF-2 Inhibitors Revenue Market Share by Players (2020-2025)
4.1.3 Global FGF-2 Inhibitors Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global FGF-2 Inhibitors Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global FGF-2 Inhibitors Key Players Headquarters & Area Served
4.4 Global FGF-2 Inhibitors Players, Product Type & Application
4.5 Global FGF-2 Inhibitors Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global FGF-2 Inhibitors Market CR5 and HHI
4.6.3 2024 FGF-2 Inhibitors Tier 1, Tier 2, and Tier 3
5 FGF-2 Inhibitors Market Size by Type
5.1 Global FGF-2 Inhibitors Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global FGF-2 Inhibitors Revenue by Type (2020-2031)
5.3 Global FGF-2 Inhibitors Revenue Market Share by Type (2020-2031)
6 FGF-2 Inhibitors Market Size by Application
6.1 Global FGF-2 Inhibitors Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global FGF-2 Inhibitors Revenue by Application (2020-2031)
6.3 Global FGF-2 Inhibitors Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Advenchen Laboratories
7.1.1 Advenchen Laboratories Comapny Information
7.1.2 Advenchen Laboratories Business Overview
7.1.3 Advenchen Laboratories FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.1.4 Advenchen Laboratories FGF-2 Inhibitors Product Portfolio
7.1.5 Advenchen Laboratories Recent Developments
7.2 ArQule
7.2.1 ArQule Comapny Information
7.2.2 ArQule Business Overview
7.2.3 ArQule FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.2.4 ArQule FGF-2 Inhibitors Product Portfolio
7.2.5 ArQule Recent Developments
7.3 AVEO Pharmaceuticals
7.3.1 AVEO Pharmaceuticals Comapny Information
7.3.2 AVEO Pharmaceuticals Business Overview
7.3.3 AVEO Pharmaceuticals FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.3.4 AVEO Pharmaceuticals FGF-2 Inhibitors Product Portfolio
7.3.5 AVEO Pharmaceuticals Recent Developments
7.4 Batu Biologics
7.4.1 Batu Biologics Comapny Information
7.4.2 Batu Biologics Business Overview
7.4.3 Batu Biologics FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.4.4 Batu Biologics FGF-2 Inhibitors Product Portfolio
7.4.5 Batu Biologics Recent Developments
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Comapny Information
7.5.2 Boehringer Ingelheim Business Overview
7.5.3 Boehringer Ingelheim FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.5.4 Boehringer Ingelheim FGF-2 Inhibitors Product Portfolio
7.5.5 Boehringer Ingelheim Recent Developments
7.6 Bristol-Myers Squibb Company
7.6.1 Bristol-Myers Squibb Company Comapny Information
7.6.2 Bristol-Myers Squibb Company Business Overview
7.6.3 Bristol-Myers Squibb Company FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.6.4 Bristol-Myers Squibb Company FGF-2 Inhibitors Product Portfolio
7.6.5 Bristol-Myers Squibb Company Recent Developments
7.7 Celon Pharma
7.7.1 Celon Pharma Comapny Information
7.7.2 Celon Pharma Business Overview
7.7.3 Celon Pharma FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.7.4 Celon Pharma FGF-2 Inhibitors Product Portfolio
7.7.5 Celon Pharma Recent Developments
7.8 Debiopharm International
7.8.1 Debiopharm International Comapny Information
7.8.2 Debiopharm International Business Overview
7.8.3 Debiopharm International FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.8.4 Debiopharm International FGF-2 Inhibitors Product Portfolio
7.8.5 Debiopharm International Recent Developments
7.9 Eddingpharm
7.9.1 Eddingpharm Comapny Information
7.9.2 Eddingpharm Business Overview
7.9.3 Eddingpharm FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.9.4 Eddingpharm FGF-2 Inhibitors Product Portfolio
7.9.5 Eddingpharm Recent Developments
7.10 Eli Lilly and Company
7.10.1 Eli Lilly and Company Comapny Information
7.10.2 Eli Lilly and Company Business Overview
7.10.3 Eli Lilly and Company FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.10.4 Eli Lilly and Company FGF-2 Inhibitors Product Portfolio
7.10.5 Eli Lilly and Company Recent Developments
7.11 Hutchison MediPharma
7.11.1 Hutchison MediPharma Comapny Information
7.11.2 Hutchison MediPharma Business Overview
7.11.3 Hutchison MediPharma FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.11.4 Hutchison MediPharma FGF-2 Inhibitors Product Portfolio
7.11.5 Hutchison MediPharma Recent Developments
7.12 Principia Biopharma
7.12.1 Principia Biopharma Comapny Information
7.12.2 Principia Biopharma Business Overview
7.12.3 Principia Biopharma FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.12.4 Principia Biopharma FGF-2 Inhibitors Product Portfolio
7.12.5 Principia Biopharma Recent Developments
7.13 Santa Cruz Biotechnology
7.13.1 Santa Cruz Biotechnology Comapny Information
7.13.2 Santa Cruz Biotechnology Business Overview
7.13.3 Santa Cruz Biotechnology FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.13.4 Santa Cruz Biotechnology FGF-2 Inhibitors Product Portfolio
7.13.5 Santa Cruz Biotechnology Recent Developments
7.14 Vichem Chemie Research
7.14.1 Vichem Chemie Research Comapny Information
7.14.2 Vichem Chemie Research Business Overview
7.14.3 Vichem Chemie Research FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.14.4 Vichem Chemie Research FGF-2 Inhibitors Product Portfolio
7.14.5 Vichem Chemie Research Recent Developments
7.15 AstraZeneca
7.15.1 AstraZeneca Comapny Information
7.15.2 AstraZeneca Business Overview
7.15.3 AstraZeneca FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.15.4 AstraZeneca FGF-2 Inhibitors Product Portfolio
7.15.5 AstraZeneca Recent Developments
7.16 Amgen
7.16.1 Amgen Comapny Information
7.16.2 Amgen Business Overview
7.16.3 Amgen FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.16.4 Amgen FGF-2 Inhibitors Product Portfolio
7.16.5 Amgen Recent Developments
7.17 Novartis
7.17.1 Novartis Comapny Information
7.17.2 Novartis Business Overview
7.17.3 Novartis FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.17.4 Novartis FGF-2 Inhibitors Product Portfolio
7.17.5 Novartis Recent Developments
7.18 Eisai
7.18.1 Eisai Comapny Information
7.18.2 Eisai Business Overview
7.18.3 Eisai FGF-2 Inhibitors Revenue and Gross Margin (2020-2025)
7.18.4 Eisai FGF-2 Inhibitors Product Portfolio
7.18.5 Eisai Recent Developments
8 North America
8.1 North America FGF-2 Inhibitors Revenue (2020-2031)
8.2 North America FGF-2 Inhibitors Revenue by Type (2020-2031)
8.2.1 North America FGF-2 Inhibitors Revenue by Type (2020-2025)
8.2.2 North America FGF-2 Inhibitors Revenue by Type (2026-2031)
8.3 North America FGF-2 Inhibitors Revenue Share by Type (2020-2031)
8.4 North America FGF-2 Inhibitors Revenue by Application (2020-2031)
8.4.1 North America FGF-2 Inhibitors Revenue by Application (2020-2025)
8.4.2 North America FGF-2 Inhibitors Revenue by Application (2026-2031)
8.5 North America FGF-2 Inhibitors Revenue Share by Application (2020-2031)
8.6 North America FGF-2 Inhibitors Revenue by Country
8.6.1 North America FGF-2 Inhibitors Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America FGF-2 Inhibitors Revenue by Country (2020-2025)
8.6.3 North America FGF-2 Inhibitors Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe FGF-2 Inhibitors Revenue (2020-2031)
9.2 Europe FGF-2 Inhibitors Revenue by Type (2020-2031)
9.2.1 Europe FGF-2 Inhibitors Revenue by Type (2020-2025)
9.2.2 Europe FGF-2 Inhibitors Revenue by Type (2026-2031)
9.3 Europe FGF-2 Inhibitors Revenue Share by Type (2020-2031)
9.4 Europe FGF-2 Inhibitors Revenue by Application (2020-2031)
9.4.1 Europe FGF-2 Inhibitors Revenue by Application (2020-2025)
9.4.2 Europe FGF-2 Inhibitors Revenue by Application (2026-2031)
9.5 Europe FGF-2 Inhibitors Revenue Share by Application (2020-2031)
9.6 Europe FGF-2 Inhibitors Revenue by Country
9.6.1 Europe FGF-2 Inhibitors Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe FGF-2 Inhibitors Revenue by Country (2020-2025)
9.6.3 Europe FGF-2 Inhibitors Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China FGF-2 Inhibitors Revenue (2020-2031)
10.2 China FGF-2 Inhibitors Revenue by Type (2020-2031)
10.2.1 China FGF-2 Inhibitors Revenue by Type (2020-2025)
10.2.2 China FGF-2 Inhibitors Revenue by Type (2026-2031)
10.3 China FGF-2 Inhibitors Revenue Share by Type (2020-2031)
10.4 China FGF-2 Inhibitors Revenue by Application (2020-2031)
10.4.1 China FGF-2 Inhibitors Revenue by Application (2020-2025)
10.4.2 China FGF-2 Inhibitors Revenue by Application (2026-2031)
10.5 China FGF-2 Inhibitors Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia FGF-2 Inhibitors Revenue (2020-2031)
11.2 Asia FGF-2 Inhibitors Revenue by Type (2020-2031)
11.2.1 Asia FGF-2 Inhibitors Revenue by Type (2020-2025)
11.2.2 Asia FGF-2 Inhibitors Revenue by Type (2026-2031)
11.3 Asia FGF-2 Inhibitors Revenue Share by Type (2020-2031)
11.4 Asia FGF-2 Inhibitors Revenue by Application (2020-2031)
11.4.1 Asia FGF-2 Inhibitors Revenue by Application (2020-2025)
11.4.2 Asia FGF-2 Inhibitors Revenue by Application (2026-2031)
11.5 Asia FGF-2 Inhibitors Revenue Share by Application (2020-2031)
11.6 Asia FGF-2 Inhibitors Revenue by Country
11.6.1 Asia FGF-2 Inhibitors Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia FGF-2 Inhibitors Revenue by Country (2020-2025)
11.6.3 Asia FGF-2 Inhibitors Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA FGF-2 Inhibitors Revenue (2020-2031)
12.2 SAMEA FGF-2 Inhibitors Revenue by Type (2020-2031)
12.2.1 SAMEA FGF-2 Inhibitors Revenue by Type (2020-2025)
12.2.2 SAMEA FGF-2 Inhibitors Revenue by Type (2026-2031)
12.3 SAMEA FGF-2 Inhibitors Revenue Share by Type (2020-2031)
12.4 SAMEA FGF-2 Inhibitors Revenue by Application (2020-2031)
12.4.1 SAMEA FGF-2 Inhibitors Revenue by Application (2020-2025)
12.4.2 SAMEA FGF-2 Inhibitors Revenue by Application (2026-2031)
12.5 SAMEA FGF-2 Inhibitors Revenue Share by Application (2020-2031)
12.6 SAMEA FGF-2 Inhibitors Revenue by Country
12.6.1 SAMEA FGF-2 Inhibitors Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA FGF-2 Inhibitors Revenue by Country (2020-2025)
12.6.3 SAMEA FGF-2 Inhibitors Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.